Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.
Histone deacetylase (Hdac) inhibitors are used clinically to treat cancer and epilepsy. Although Hdac inhibition accelerates osteoblast maturation and suppresses osteoclast maturation in vitro, the effects of Hdac inhibitors on the skeleton are not understood. The purpose of this study was to determine how the pan-Hdac inhibitor, suberoylanilide hydroxamic acid (SAHA; a.k.a. vorinostat or Zolinza(TM)) affects bone mass and remodeling in vivo. Male C57BL/6J mice received daily SAHA (100mg/kg) or vehicle injections for 3 to 4weeks. SAHA decreased trabecular bone volume fraction and trabecular number in the distal femur. Cortical bone at the femoral midshaft was not affected. SAHA reduced serum levels of P1NP, a bone formation marker, and also suppressed tibial mRNA levels of type I collagen, osteocalcin and osteopontin, but did not alter Runx2 or osterix transcripts. SAHA decreased histological measures of osteoblast number but interestingly increased indices of osteoblast activity including mineral apposition rate and bone formation rate. Neither serum (TRAcP 5b) nor histological markers of bone resorption were affected by SAHA. P1NP levels returned to baseline in animals which were allowed to recover for 4weeks after 4weeks of daily SAHA injections, but bone density remained low. In vitro, SAHA suppressed osteogenic colony formation, decreased osteoblastic gene expression, induced cell cycle arrest, and caused DNA damage in bone marrow-derived adherent cells. Collectively, these data demonstrate that bone loss following treatment with SAHA is primarily due to a reduction in osteoblast number. Moreover, these decreases in osteoblast number can be attributed to the deleterious effects of SAHA on immature osteoblasts, even while mature osteoblasts are resistant to the harmful effects and demonstrate increased activity in vivo, indicating that the response of osteoblasts to SAHA is dependent upon their differentiation state. These studies suggest that clinical use of SAHA and other Hdac inhibitors to treat cancer, epilepsy or other conditions may potentially compromise skeletal structure and function.
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Meghan E
ME
McGee-Lawrence
Angela L
AL
McCleary-Wheeler
Frank J
FJ
Secreto
David F
DF
Razidlo
Minzhi
M
Zhang
Bridget A
BA
Stensgard
Xiaodong
X
Li
Gary S
GS
Stein
Jane B
JB
Lian
Jennifer J
JJ
Westendorf
D000107:Acetylation / Q000187:drug effects; D000818:Animals; D015415:Biomarkers / Q000097:blood; D001835:Body Weight / Q000187:drug effects; D001854:Bone Marrow Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D016723:Bone Remodeling / Q000187:drug effects; D001862:Bone Resorption / Q000097:blood / Q000139:chemically induced*; D002452:Cell Count; D002453:Cell Cycle / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects*; D003114:Colony-Forming Units Assay; D004249:DNA Damage; D005269:Femur / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D005786:Gene Expression Regulation / Q000187:drug effects; D006657:Histones / Q000378:metabolism; D006877:Hydroxamic Acids / Q000009:adverse effects* / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D010012:Osteogenesis / Q000187:drug effects; D010446:Peptide Fragments / Q000378:metabolism; D011347:Procollagen / Q000378:metabolism; D013997:Time Factors; D000077337:Vorinostat
D015415:Biomarkers; D006657:Histones; D006877:Hydroxamic Acids; D010446:Peptide Fragments; D011347:Procollagen; C047202:procollagen Type I N-terminal peptide; D000077337:Vorinostat
J Bone Miner Res. 2005 Dec;20(12):2254-63
16294278
Nat Genet. 2009 Nov;41(11):1199-206
19801982
Eur J Haematol. 2010 Mar;84(3):201-11
19929977
Mol Cell Biol. 2002 Nov;22(22):7982-92
12391164
Pediatrics. 2001 Dec;108(6):E107
11731634
Blood. 2007 Jan 1;109(1):31-9
16960145
Nucleic Acids Res. 2001 May 1;29(9):e45
11328886
Pharmacol Res. 2004 Jul;50(1):93-7
15082034
FASEB J. 2009 Dec;23(12):4266-75
19723705
Int J Cancer. 2007 Aug 1;121(3):656-65
17417771
Neurology. 2001 Aug 14;57(3):445-9
11502911
Proteomics. 2010 Mar;10(5):1029-39
20049865
Cell. 2004 Nov 12;119(4):555-66
15537544
Crit Rev Eukaryot Gene Expr. 2007;17(3):187-96
17725488
Nat Med. 2007 Nov;13(11):1299-307
17922010
Bioinformation. 2008;3(5):218-22
19255637
Br J Pharmacol. 2007 Apr;150(7):862-72
17325656
Oncologist. 2007 Oct;12(10):1247-52
17962618
J Clin Oncol. 2005 Jun 10;23(17):3923-31
15897550
J Cell Physiol. 2010 Nov;225(2):537-44
20458754
Epilepsia. 2001 Sep;42(9):1141-7
11580761
Mol Cell. 2002 Jan;9(1):45-57
11804585
Science. 2009 Aug 14;325(5942):834-40
19608861
J Biol Chem. 2010 May 7;285(19):14663-70
20190228
J Bone Miner Res. 2008 Mar;23(3):361-72
17997710
Epilepsia. 2010 Jun;51(6):984-93
20163440
J Biol Chem. 2006 Jun 16;281(24):16502-11
16613856
J Bone Miner Res. 1987 Dec;2(6):595-610
3455637
J Paediatr Child Health. 2004 Aug;40(8):470-3
15265190
Pediatr Neurol. 2006 Sep;35(3):177-81
16939856
Genes Dev. 2009 Jul 15;23(14):1625-30
19605684
Mol Cancer Ther. 2010 Dec;9(12):3210-20
21159607
Gene. 2011 Mar 15;474(1-2):1-11
21185361
J Biol Chem. 2001 Sep 28;276(39):36734-41
11473107
Seizure. 2007 Jan;16(1):22-34
17110134
PLoS One. 2010 Jul 09;5(7):e11492
20628553
Nat Rev Genet. 2009 Jan;10(1):32-42
19065135
Exp Mol Med. 2007 Apr 30;39(2):213-21
17464183
Biochem Pharmacol. 1981 Jun 1;30(11):1364-6
6791653
Tissue Eng. 2006 Oct;12(10):2927-37
17518660
Mol Cell Biol. 2008 Mar;28(5):1688-701
18180281
Am J Geriatr Psychiatry. 2010 Mar;18(3):245-55
20224520
Cancer. 2009 Dec 1;115(23):5541-9
19711464
Mol Endocrinol. 2006 Oct;20(10):2432-43
16728531
Nature. 2000 Nov 16;408(6810):377-81
11099047
J Pediatr. 1995 Aug;127(2):256-62
7636651
Int J Biochem. 1993 Nov;25(11):1631-5
8288032
J Clin Invest. 2009 Dec;119(12):3666-77
19920351
J Bone Miner Res. 2010 Jul;25(7):1468-86
20533309
Int J Toxicol. 2010 Jan-Feb;29(1):3-19
19903873
Epilepsia. 2004 Nov;45(11):1330-7
15509233
Epilepsia. 2007 Oct;48(10):1850-60
17634065
J Clin Oncol. 2007 Jul 20;25(21):3109-15
17577020
Gene. 2005 Dec 19;363:15-23
16289629
J Clin Neurosci. 2004 Nov;11(8):854-8
15519862
J Biol Chem. 2004 Oct 1;279(40):41998-2007
15292260
EMBO J. 2005 Jul 20;24(14):2543-55
15990875
Cell Prolif. 2009 Dec;42(6):711-20
19689470
Science. 2005 Jan 14;307(5707):269-73
15653507
Cell Immunol. 2008 May-Jun;253(1-2):66-70
18579124
Cancer Res. 2000 Sep 15;60(18):5165-70
11016644
Epilepsy Behav. 2007 Mar;10(2):291-5
17224308
Pediatr Int. 2002 Jun;44(3):247-53
11982890
Nat Chem Biol. 2010 Jan;6(1):25-33
19966789
J Biol Chem. 2000 Jul 7;275(27):20436-43
10777477
J Neurochem. 1979 Jun;32(6):1769-80
376783
J Cell Biochem. 2005 Oct 15;96(3):533-42
16088945
Stem Cells Dev. 2009 May;18(4):573-81
18694296
J Pediatr Endocrinol Metab. 2006 Apr;19(4):529-34
16759039